Division of Hematology and Medical Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, San Antonio, TX 78229, United States.
World J Gastroenterol. 2010 Nov 21;16(43):5518-22. doi: 10.3748/wjg.v16.i43.5518.
A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report. The patient showed disease progression on sorafenib therapy demonstrated by computed tomography scans as well as serial serum α-fetoprotein (AFP) elevation. After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP. Mammalian target of rapamycin inhibitors including sirolimus alone or in conjunction with sorafenib may be useful in the treatment of post transplant HCC.
本报告介绍了一例肝癌（HCC）患者，该患者在 HCC 肝移植后出现肺部复发。该患者在索拉非尼治疗期间疾病进展，通过计算机断层扫描（CT）以及连续的血清甲胎蛋白（AFP）升高显示。在他的免疫抑制治疗成功转换为西罗莫司并继续使用索拉非尼后，根据 RECIST 标准，他达到部分缓解，AFP 恢复正常。雷帕霉素靶蛋白抑制剂（mTORI），包括西罗莫司单药或与索拉非尼联合使用，可能对移植后 HCC 的治疗有效。
